Use of nitazoxanide for gastrointestinal tract infections: Treatment of protozoan parasitic infection and beyond

Current Infectious Disease Reports

Volumn 8, Issue 2, 2006, Pages 91-95

  Bobak, David A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTIPROTOZOAL AGENT; AZITHROMYCIN; CLARITHROMYCIN; DICLAZURIL; MEBENDAZOLE; METRONIDAZOLE; NITAZOXANIDE; PAROMOMYCIN; PRAZIQUANTEL; QUINFAMIDE; RIFABUTIN; TIZOXANIDE; TIZOXANIDE GLUCURONIDE; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL PAIN; ABNORMAL URINE COMPOSITION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIPROTOZOAL ACTIVITY; ARTHRALGIA; BACTERIUM; BLOOD DISEASE; CARDIOVASCULAR DISEASE; CENTRAL AMERICA; CESTODE; CHILL; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CREATININE BLOOD LEVEL; CRYPTOSPORIDIUM PARVUM; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FEVER; DRUG FORMULATION; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; DYSURIA; EPISTAXIS; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; GIARDIA LAMBLIA; HUMAN; HYPESTHESIA; INFECTIOUS DIARRHEA; LD 50; LEUKOCYTOSIS; MALAISE; MEDICAL RESEARCH; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEMATODE; NEUROLOGIC DISEASE; NONHUMAN; PHARYNGITIS; PROTOZOAL INFECTION; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; SOUTH AMERICA; STRUCTURE ACTIVITY RELATION; SUSPENSION; SWEAT GLAND DISEASE; SYNCOPE; TABLET; TACHYCARDIA; TERATOGENICITY; TREMATODE; UNITED STATES; UROGENITAL TRACT DISEASE; VOMITING;

EID: 33645302948     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0003-y     Document Type: Review

References (35)

1. Rossignol JF, Cavier R: New derivative of 2-benzamino-5-nitrothiazoles. Chem Abstr 1975, 83:28216n.
2. White CA Jr: Nitazoxanide: a new broad spectrum anti-parasitic agent. Expert Rev Anti Infect Ther 2004, 2:43-49.
3. Bailey JM, Erramouspe J: Nitazoxanide treatment for giardiasis and cryptosporidiosis in children. Ann Pharmacother 2004, 38:634-640.
4. Fox LM, Saravolatz LD: Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005, 40:1173-1178.
5. Ochoa TJ, White AC Jr: Nitazoxanide for treatment of intestinal parasites in children. Pediatr Infect Dis J 2005, 24:641-642.
6. Megraud F, Occhialini A, Rossignol JF: Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother 1998, 42:2836-2840.
7. Guttner Y, Windsor HM, Viiala CH, et al.: Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study. Antimicrob Agents Chemother 2003, 47:3780-3783.
8. Dubreuil L, Houcke I, Mouton Y, Rossignol JF: In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996, 40:2266-2267.
9. McVay CS, Rolfe RD: In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000, 44:2254-2258.
10. Alinia, nitazoxanide [product information]. Tampa, FL: Romark Pharmaceuticals; 2004-2005.
11. Nitazoxanide. In USP DI® Drug Information for the Healthcare Professional [electronic version]. Edited by Klasco RK. Greenwood Village, CO: Thomson Micromedex; 2005.
12. Nitazoxanide. In Martindale: The Complete Drug Reference. Edited by Sweetman SC. London: Pharmaceutical Press; 2005.
13. Drugs for parasitic infection. Med Lett Drugs Ther 2004, 46: 1-12.
14. Romark Labortories: Romark completes clinical study of Alinia in treating Clostridium difficile-associated disease [press release]. http://www.romark.com/index.php/median_center/press_releases/34.html. Accessed November 18, 2005.
15. Romark Labortories: Romark advances development of Alinia in treating Clostridium difficile-associated disease [press release]. http://www.romark.com/index. php/mediaņter/press_releases/33.html. Accessed December 8, 2005.
16. Smith HV, Corcoran GD: New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004, 17:557-564.
17. Zardi EM, Picardi A, Afeltra A: Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy 2005, 51: 193-196.
18. Huang DB, Chappell C, Okhuysen PC: Cryptosporidiosis in children. Semin Pediatr Infect Dis 2004, 15:253-259.
19. Lebwohl B, Deckelbaum RJ, Green PH: Giardiasis. Gastrointest Endosc 2003, 57:906-913.
20. Thompson RC, Monis PT: Variation in Giardia: implications for taxonomy and epidemiology. Adv Parasitol 2004, 58:69-137.
21. Caccio SM, Thompson RC, McLauchlin J, Smith HV: Unraveling Cryptosporidium and Giardia epidemiology. Trends Parasitol 2005, 21:430-437.
22. Ortiz JJ, Ayoub A, Gargala G, et al.: Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001, 15: 1409-1415.
23. Adagu IS, Nolder D, Warhurst DC, Rossignol JF: In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica, and Trichomonas vaginalis. J Antimicrob Chemother 2002, 49:103-111.
24. Davila-Gutierrez CE, Vasquez C, Trujillo-Hernandez B, Huerta M: Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am J Trop Med Hyg 2002, 66:251-254.
25. Dillingham RA, Lima AA, Guerrant RL: Cryptosporidiosis: epidemiology and impact. Microbes Infect 2002, 4:1059-1066.
26. Chen XM, Keithly JS, Paya CV, LaRusso NF: Cryptosporidiosis. N Engl J Med 2002, 346:1723-1731.
27. Xiao L, Fayer R, Ryan U, Upton SJ: Cryptosporidium taxonomy: recent advances and implications for public health. Clin Microbiol Rev 2004, 17:72-97.
28. Rossignol JF, Ayoub A, Ayers MS: Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001, 184:103-106.
29. Amadi B, Mwiya M, Musuku J, et al.: Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002, 360:1375-1380.
30. Rossignol JF, Hidalgo H, Feregrino M, et al.: A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosponidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998, 92:663-666.
31. Juan JO, Lopez Chegne N, Gargala G, Favennec L: Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascaniasis, trichuniasis and hymenolepiasis in children from Peru. Trans R Soc Trop Med Hyg 2002, 96:193-196.
32. Diaz E, Mondragon J, Ramirez E, Bernal R: Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg 2003, 68:384-385.
33. Walker M, Rossignol JF, Torgerson P, Hemphill A: In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. J Antimicrob Chemother 2004, 54:609-616.
34. Stettler M, Fink R, Walker M, et al.: In vitro parasiticidal effect of nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2003, 47:467-474.
35. Favennec L, Jave Ortiz J, Gargala C, et al.: Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 2003, 17:265-270.